Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2015-10-16 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
七届二十三次监事会决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 23rd meeting of the 7th Supervisory Board of Kunming Pharmaceutical Group Co., Ltd. It includes voting results on amendments to the company's articles of association and the nomination of candidates for the 8th Supervisory Board. It also provides brief biographies of the candidates. There are no financial statements, audit opinions, or detailed management discussions. The document is a formal announcement related to board/supervisory committee matters, specifically about board member nominations and resolutions. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report or a notice of a report publication, so it is not RPA or RNS.
2015-10-16 Chinese
关于追加2015年日常关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the addition of daily related-party transactions for the year 2015. It details the approval process by the board and independent directors, the nature and amount of the related-party transactions, the relationship between the parties, pricing policies, and the impact on the company and shareholders. The document is a formal announcement about related-party transactions and does not contain financial statements or comprehensive financial data. It is not an annual or interim report, audit report, or earnings release. It is also not a regulatory certification or a report publication announcement. The content fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about related-party transactions that does not fit into more specific categories.
2015-10-16 Chinese
七届四十八次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 48th meeting of the 7th Board of Directors of Kunming Pharmaceutical Group Co., Ltd. It includes voting results, proposals for board candidates, and other board decisions. The content focuses on board meeting decisions and candidate nominations, which is characteristic of Board/Management Information filings. The document is not an annual report, audit report, or earnings release, nor is it a proxy statement or shareholder meeting result announcement. It is a formal disclosure of board resolutions and management changes, fitting the Board/Management Information (MANG) category. The document length is 4356 characters, which is sufficient for a detailed board meeting announcement rather than a brief report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2015-10-16 Chinese
独立董事关于公司提名聘任第八届董事会独立董事的独立意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors regarding the nomination and appointment of independent directors for the company's eighth board. It references compliance with company law and articles of association, and it is an independent opinion on the nomination process. This is related to board or management information, specifically about board member appointments. The document is short and does not contain financial data or detailed reports, so it is not an annual report or financial filing. Therefore, it fits best under Board/Management Information (MANG).
2015-10-16 Chinese
关于修订公司章程的公告
Governance Information Classification · 95% confidence The document is an announcement regarding amendments to the company's articles of association (公司章程). It details changes in the number of vice chairpersons and supervisors, reflecting governance structure adjustments. The document mentions board and supervisory meetings approving the amendments and the need for shareholder meeting approval. It is not a full report but a formal announcement about governance changes. This fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is short and focused on governance amendments, not financial data or voting results.
2015-10-16 Chinese
关于实际控制人、管理层人员增持公司股份计划实施完成的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the completion of a shareholding increase plan by the actual controller and management personnel of the company. It details the number of shares increased, the persons involved, and their shareholding percentages after the increase. It does not contain financial statements or detailed financial performance data. The document is a formal disclosure of insider share transactions by directors and executives, which fits the definition of Director's Dealing (DIRS). The document length is 2315 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is DIRS.
2015-10-13 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.